欢迎访问药物流行病学杂志网站！

设为首页加入收藏

国家科技部中国科技论文统计源期刊

中国科技核心期刊

WHO西太平洋地区医学索引(WPRIM)收录期刊

湖北优秀期刊

《药物流行病学杂志》官方网站与投审稿系统变更通知<点击查看详情>

双歧三联活菌胶囊联合瑞舒伐他汀对高脂血症患者血脂及肠道菌群的影响

Influence of Bifid Triple Viable Capsules Combined with Rosuvastatin on Blood Fat and Intestinal Flora on Patients with Hyperlipemia

DOI：

中文关键词: 高脂血症瑞舒伐他汀双歧三联活菌胶囊血脂肠道菌群

英文关键词:Hyperlipemia Rosuvastatin Bifid triple viable capsules Blood fat Intestinal flora

基金项目:

作者	单位
梁崇志^① 许婉芬^②	台州市路桥区第二人民医院 ①药剂科；②内科（浙江台州318058）

摘要点击次数: 1850

全文下载次数: 1178

中文摘要:

摘要目的:探讨双歧三联活菌胶囊联合瑞舒伐他汀对高脂血症患者血脂及肠道菌群的影响。方法：80例高脂血症患者随机分为观察组和对照组各40例。对照组予瑞舒伐他汀片10 mg，po qd；观察组在此基础上加用双歧三联活菌胶囊630 mg，po tid。两组疗程均为12周。观察两组治疗前后总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)水平，及肠道菌群(双歧杆菌、乳酸杆菌、大肠埃希菌和粪肠球菌)变化，比较两组药品不良反应发生情况。结果：治疗12周后，两组TC、TG和LDL-C水平较前均明显下降，HDL-C水平明显上升(P<0.05或P<0.01)，且治疗后观察组各项血脂指标均明显优于对照组(P<0.05)。两组双歧杆菌和乳酸杆菌、粪肠球菌数量较前明显上升，大肠埃希菌数量明显下降(P<0.05或P<0.01)，且观察组变化幅度比对照组更明显(P<0.05)。两组药品不良反应发生率比较，差异无统计学意义(P>0.05)。结论：双歧三联活菌胶囊联合瑞舒伐他汀治疗高脂血症患者的降脂疗效显著，安全性较好，与双歧三联活菌调节并纠正肠道微生态失衡，恢复肠道有益菌数量密切相关。

英文摘要:

ABSTRACT Objective: To discuss influence of bifid triple viable capsules combined with rosuvastatin on blood fat and intestinal flora on patients with hyperlipemia.Methods:80 cases of patients with hyperlipemia were divided into observation group and control group with 40 cases in either group randomly. The patients in control group were given 10mg rosuvastatin per time through the mouth, once a day, and the patients in observation group were additionally given 630mg bifid triple viable capsules, three times a day with warm boiled water through the mouth the course of treatment of two groups were both 12 weeks. The changes of blood fat indexes [total cholesterol (TC), triglyceride (TG), high density lipoprotein cholesterol (HDL-C), and low density lipoprotein cholesterol (LDL-C)] levels and intestinal flora (Bifidobacterium, Lactobacillus, Bacillus coli and Enterococcus faecalis) of patients in two groups were observed before and 12 weeks after treatment, and the adverse drug reaction (ADR) during treatment were compared as well. Results:After 12 weeks’ treatment, TC, TG and LDL-C levels of patients in two groups were obviously declined than before, while HDL C levels were obviously rose than before (P<0.05 orP<0.01), and the changing rate in observation group was much higher than that in control group (P<0.05). Meanwhile, the quantities of Bifidobacterium, Lactobacillus and Enterococcus faecalis of patients in two groups were obviously rose than before, while the quantities of Bacillus coli were obviously declined than before (P<0.05or P<0.01), and the changing rate of patients in observation group was much higher than that in control group (P<0.05). Comparing with the occurrence rates of ADR, no statistical differences were appeared (P>0.05).Conclusion:Bifid triple viable capsules combined with rosuvastatin had significant curative effect on patients with hyperlipemia with high security, whose mechanism had close effect on adjusting and correcting the imbalance of intestinal microecology, recovering the quantities of intestinal available bacteria.

查看全文查看/发表评论下载PDF阅读器

关闭